the U.S. Food and Drug Administration (FDA) has approved Herceptin^® (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

http://www.businesswire.com/news/home/20101020007322/en